Sherri Kroll
Psychiatric/Mental Health · Brunswick, GANPI 1437309861
Payments from drug & device makers
Across 849 payments — averaging $183.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$94K
- Axsome Therapeutics, Inc.$25K
- Johnson & Johnson$22K
- Teva Pharmaceuticals USA, Inc.$5K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$673
- plus $6K from 24 others
What the payments were for
- Consulting fees$12,8388%
- Speaking & faculty fees$118,02276%
- Travel & lodging$9,5186%
- Food & beverage$15,03110%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 245 | $94,275 |
| Axsome Therapeutics, Inc. | 55 | $25,022 |
| Johnson & Johnson | 100 | $22,060 |
| Teva Pharmaceuticals USA, Inc. | 70 | $5,322 |
| Otsuka America Pharmaceutical, Inc. | 61 | $2,414 |
| Neurocrine Biosciences, Inc. | 44 | $673 |
| Alkermes, Inc. | 36 | $665 |
| E.r. Squibb & Sons, L.L.C. | 19 | $536 |
| Tris Pharma Inc | 25 | $487 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $460 |
| Vanda Pharmaceuticals Inc. | 15 | $409 |
| Almatica Pharma LLC | 15 | $297 |
| Corium, LLC | 14 | $291 |
| Neuronetics, Inc. | 5 | $284 |
| Lundbeck LLC | 15 | $273 |
| Bausch Health US, LLC | 16 | $273 |
| Ironshore Pharmaceuticals Inc. | 14 | $242 |
| Indivior Inc. | 13 | $235 |
| Neos Therapeutics, LP | 13 | $230 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $213 |
| Braeburn Inc. | 10 | $196 |
| Supernus Pharmaceuticals, Inc. | 9 | $191 |
| Avanir Pharmaceuticals, Inc. | 8 | $140 |
| Sunovion Pharmaceuticals Inc. | 5 | $82 |
| Collegium Pharmaceutical, Inc. | 3 | $66 |
| Noven Therapeutics, LLC | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$90,301
- Auvelity$23,930
- SPRAVATO$20,589
- Austedo XR$2,600
- AUSTEDO$1,689
- ABILIFY MAINTENA$1,288
- COBENFY$264
- NEUROSTAR TMS THERAPY SYSTEM$193
- REXULTI$124
- ABILIFY ASIMTUFII$122
- Fanapt$122
- VIVITROL$117
How this compares
$155,476 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 65 | $109,213 |
| Invega SustennaPaliperidone Palmitate | 23 | $65,355 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $30,588 |
| TrintellixVortioxetine Hydrobromide | 28 | $15,594 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $15,092 |
| SpravatoEsketamine Hcl | 12 | $14,374 |
| Lurasidone Hcl | 22 | $3,402 |
| Trazodone Hcl | 187 | $2,899 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $2,620 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 32 | $2,503 |
| Duloxetine Hcl | 100 | $2,067 |
| Fluphenazine Hcl | 12 | $1,878 |
| Alprazolam XrAlprazolam | 16 | $1,631 |
| Bupropion XlBupropion Hcl | 116 | $1,288 |
| Eszopiclone | 61 | $1,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $94,275 | $109,21365 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $22,060 | $79,72935 claims |
| Alkermes, Inc.Lybalvi | $665 | $30,58820 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $460 | $15,59428 claims |
| Axsome Therapeutics, Inc.Auvelity | $25,022 | $15,09212 claims |
| Almatica Pharma LLCSertraline Hcl | $297 | $16735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Brunswick
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
- Bradley MosherSuwanee$13K
- Mia MisonSuwanee$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.